Currently Viewing:
Newsroom
Currently Reading
What We're Reading: Price Hikes for Older Drugs; FDA Shifts Resources; Opioids and Birth Defects
January 18, 2019 – AJMC Staff
What We're Reading: FDA Resumes Some Inspections; Walmart Leaves CVS' PBM Networks; Flu Season
January 16, 2019 – AJMC Staff
What We're Reading: Shutdown Stirs Pharma Worries; Judge Extends Birth Control Ruling; Providers Walk Tightrope
January 15, 2019 – AJMC Staff
This Week in Managed Care: January 11, 2019
January 11, 2019
Gottlieb Touts Launch of New FDA Office to Improve Drug Review Process
January 09, 2019 – Jaime Rosenberg
5 Things About the Orphan Drug Act
January 04, 2019 – Laura Joszt
How the Partial Government Shutdown Will Affect Healthcare
December 26, 2018 – Jaime Rosenberg
What We're Reading: Medicaid Work Requirements; Orphan Drug Designations; OUD Drug Gets Approved
December 26, 2018 – AJMC Staff
FDA Grants Accelerated Approval to Pembrolizumab for MCC
December 21, 2018 – Samantha DiGrande

What We're Reading: Price Hikes for Older Drugs; FDA Shifts Resources; Opioids and Birth Defects

AJMC Staff
Amid drug shortages and recalls, at least 3 sellers of a widely used blood-pressure medication, valsartan, have raised prices since a series of safety-related recalls of the drug by other manufacturers; the FDA is attempting to conserve dwindling resources during the government shutdown by prioritizing drug applications; researchers are looking into a possible link between prescription opioids and a birth defect called gastroschisis.

Manufacturers Raise Prices of Older Drugs Despite Recalls, Shortages

Amid drug shortages and recalls, at least 3 sellers of a widely used blood-pressure medication, valsartan, have raised prices since a series of safety-related recalls of the drug by other manufacturers, The Wall Street Journal reported. In addition, of the nearly 120 drugs listed by the FDA as currently or recently in shortage, about one-third had price increases after the shortages started, according to the paper’s review of pricing data provided by RELX Group’s Elsevier health-information unit.



FDA Prioritizes Drug Reviews by Shifting Resources

The FDA is attempting to conserve dwindling resources during the government shutdown by prioritizing drug applications, The Washington Post reported. Commissioner Scott Gottlieb, MD, told the paper that the measures will only help preserve funds for a few weeks, and not months, if the shutdown is protracted. The 2018 fees are expected to run out about February 8, and the agency isn’t allowed to collect the 2019 fees during the shutdown, although it can shift funds from other activities.



Researchers Investigating Link Between Birth Defect, Opioids

Researchers are looking into a possible link between prescription opioids and a birth defect called gastroschisis, the Associated Press reported. The condition causes an infant to be born with its intestines outside the stomach due to a hole in the abdominal wall. Most are repaired through surgery. Roughly 1800 such cases happen annually, but the number has been rising and officials don't know why.

Related Articles

Unraveling the Complexity of Drug Shortages
What We're Reading: Drug Prices During Shortages; Healthcare and Small Businesses; Federal Employee Premiums
Gottlieb Touts Launch of New FDA Office to Improve Drug Review Process
What We're Reading: Democrats Aim at Drug Prices; Judge Hears Birth Control Case; ACA Abortion Rule Fight
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up